首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Cyclin D1 expression and retinoblastoma gene protein (pRB) expression in esophageal squamous cell carcinoma
【24h】

Cyclin D1 expression and retinoblastoma gene protein (pRB) expression in esophageal squamous cell carcinoma

机译:食管鳞状细胞癌中Cyclin D1和视网膜母细胞瘤基因蛋白(pRB)的表达

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose: Alterations in the cell cycle regulatory cyclin/retinoblastoma protein (pRB) pathway play a important role in tumor progression in esophageal squamous cell carcinoma (ESCC). In the present study, we evaluated the prognostic significance of the combined analysis of cyclin D1 and pRB in ESCC retrospectively. Methods: Immunoreactivities of cyclin D1 and pRB were evaluated in 148 surgically resected ESCC by use of monoclonal antibodies. Disease-free survival of patients was compared among the four subgroups according to the phenotypes of cyclin D1 and pRB expressions. Results: High immunoreactivities of pRB and cyclin D1 were detected in 64.2% and 40.5% of tumors, respectively. The loss of pRB expression and overexpression of cyclin D1 correlated with short survival. However, these factors were not detected as independently prognostic in multivariate analysis. In 107 surviving patients who underwent curative operation, co-expressed pRB and cyclin D1 (pRB+/cyclin D1+: 29 patients) were correlated with unfavorable prognosis (disease-free 5-year survival rate: 42.7%) and high cancer recurrence rate (44.8%) compared with that of 40 patients with pRB+/cyclin D1- tumors (70.5% and 27.5%). The disease-free 5-year survival rate of patients with pRB+/cyclin D1- tumors was significantly better than that of other groups (P=0.001). However, the disease-free 5-year survival rate of 29 patients with pRB+/cyclin D1+ tumors was equivalent to that of 29 patients with pRB-/cyclin D1- tumors (48.3%), and that of nine patients with pRB-/cyclin D1+ tumors (22.2%, P=0.237). Conclusions: Our results suggest that overexpression of cyclin D1 may suppress pRB function, and that combined analysis of pRB and cyclin D1 may be a useful parameter of patient prognosis in ESCC.
机译:目的:细胞周期调控细胞周期蛋白/视网膜母细胞瘤蛋白(pRB)途径的改变在食管鳞状细胞癌(ESCC)的肿瘤进展中起重要作用。在本研究中,我们回顾性地评估了细胞周期蛋白D1和pRB联合分析在ESCC中的预后意义。方法:使用单克隆抗体在148例经手术切除的ESCC中评估细胞周期蛋白D1和pRB的免疫反应性。根据细胞周期蛋白D1和pRB表达的表型,在四个亚组中比较了患者的无病生存期。结果:分别在64.2%和40.5%的肿瘤中检测到pRB和cyclin D1的高免疫反应性。 pRB表达的丧失和细胞周期蛋白D1的过表达与生存期短有关。但是,在多变量分析中未将这些因素检测为独立的预后因素。在107例行手术治愈的存活患者中,共表达pRB和cyclin D1(pRB + / cyclin D1 +:29例患者)与不良预后(无疾病的5年生存率:42.7%)和高癌症复发率(44.8)相关。 %)与40例pRB + / cyclin D1-肿瘤患者(70.5%和27.5%)相比。 pRB + / cyclin D1-肿瘤患者的5年无病生存率显着高于其他组(P = 0.001)。然而,29例pRB + / cyclin D1 +肿瘤的无病5年生存率与29例pRB- / cyclin D1肿瘤的患者(48.3%)以及9例pRB- / cyclin D1肿瘤的患者相等。 D1 +肿瘤(22.2%,P = 0.237)。结论:我们的结果表明,cyclin D1的过表达可能抑制pRB功能,而pRB和cyclin D1的联合分析可能是ESCC患者预后的有用参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号